| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/01/2006 | WO2006056471A1 5-hydroxy-benzothiazole derivatives having beta-2-adrenorecptor agonist activity |
| 06/01/2006 | WO2006056449A1 Copper melphalan and copper tegafur used as anti-tumoral agents |
| 06/01/2006 | WO2006056427A1 Novel 4-arylamino pyridone derivatives as mek inhibitors for the treatment of hyperproliferative disorders |
| 06/01/2006 | WO2006056399A2 Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
| 06/01/2006 | WO2006056308A2 Flavonoid complexes with cyclodextrins |
| 06/01/2006 | WO2006056182A1 Novel active substances for treating, diagnosing and preventing macular degeneration |
| 06/01/2006 | WO2006056145A2 Osmotic device containing a venlafaxine salt and a salt having a common ion |
| 06/01/2006 | WO2006056144A2 Osmotic device containing licofelone |
| 06/01/2006 | WO2006056142A1 Cpg single-strand deoxynucleotides for use as adjuvant |
| 06/01/2006 | WO2006056129A1 Compositions of huperzia serrata alkaloids comprising huperzine a and huperzine b and preparation thereof |
| 06/01/2006 | WO2006056079A1 Formulations of pyridoxal -5'-phosphate and methods of preparation |
| 06/01/2006 | WO2006056078A1 Novel formulation of pyridoxal 5'-phosphate and method of preparation |
| 06/01/2006 | WO2006056064A1 Solid formulations of liquid biologically active agents |
| 06/01/2006 | WO2006056054A1 Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels |
| 06/01/2006 | WO2006056047A1 Cathepsin cysteine protease inhibitors |
| 06/01/2006 | WO2006056042A1 Nsaid compositions exhibiting clinical superiority |
| 06/01/2006 | WO2006056038A1 Pyridoxal-5-phosphate and stent for the treatment and prevention of atherosclerosis and restenosis |
| 06/01/2006 | WO2006056007A1 Inhibitors of biotin protein ligase |
| 06/01/2006 | WO2006042389B1 Hydroalcoholic extract of erythrina mulungu, pharmaceutical compositions and processes for producing these substances |
| 06/01/2006 | WO2006041878A3 Primary examiner |
| 06/01/2006 | WO2006041830A3 Cgrp receptor antagonists |
| 06/01/2006 | WO2006039551A3 Local administration of retinoids to treat deficiencies in dark adaptation |
| 06/01/2006 | WO2006038923A3 Aryl substituted imidazonaphthyridines |
| 06/01/2006 | WO2006038070A3 Compositions and methods for modulating gated ion channels |
| 06/01/2006 | WO2006037981A8 Inhibition of tumour cell migration |
| 06/01/2006 | WO2006037050A3 Methods for treating congestive heart failure |
| 06/01/2006 | WO2006037031A3 Formulations and methods for treatment of inflammatory diseases |
| 06/01/2006 | WO2006036015A3 6- (pyridinyl) -4-pyrimidone derivates as tau protein kinase 1 inhibitors |
| 06/01/2006 | WO2006034510A3 Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease |
| 06/01/2006 | WO2006034390A3 Inhibitors of 15-lipoxygenase |
| 06/01/2006 | WO2006033844A3 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide kcnq potassium channel modulators |
| 06/01/2006 | WO2006032146A8 The use of a modafinil compound for the treatment of problem gambling |
| 06/01/2006 | WO2006031929A3 Thiazolopyridine kinase inhibitors |
| 06/01/2006 | WO2006031848A3 Corticosteroid topical dispersion with low content of surfactant |
| 06/01/2006 | WO2006031337A3 Combinations of pkc activators and pkc inhibitors for alzheimer’s disease treatment and cognitive enhancement |
| 06/01/2006 | WO2006030300A3 Processes for the preparation of olanzapine |
| 06/01/2006 | WO2006030211A3 Acyclic sulphonamides |
| 06/01/2006 | WO2006029020A3 Treatments of refractory cancers using na+/k+-atpase inhibitors |
| 06/01/2006 | WO2006028957A8 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms |
| 06/01/2006 | WO2006028831A3 Compositions comprising 5-amino-2-hydroxybenzoic acid and a reducing sugar |
| 06/01/2006 | WO2006028523A3 Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors |
| 06/01/2006 | WO2006027692A3 Methods of treating cognitive disorders using pyridyloxymethyl and benzisoxazole azabicyclic derivatives |
| 06/01/2006 | WO2006025708A3 Inhibitor for acetylcholinesterase containing gamma-viniferin or visitin a |
| 06/01/2006 | WO2006023866A3 Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1 |
| 06/01/2006 | WO2006023617A3 Cyclic amide & ester pyrazinoylguanidine sodium channel blockers |
| 06/01/2006 | WO2006021807A3 Methods of diagnosis of attention deficit hyperactivity disorder (adhd) |
| 06/01/2006 | WO2006020916A3 Modulators of ppar and methods of their preparation |
| 06/01/2006 | WO2006020403A3 3-halo-2-oxopropionate salts and esters as novel anticancer agents |
| 06/01/2006 | WO2006019430A3 Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells |
| 06/01/2006 | WO2006019353A9 Composition and method for the treatement of psoriasis |
| 06/01/2006 | WO2006019300A3 Immune stimulatory infant nutrition |
| 06/01/2006 | WO2006018185A8 Dihydropteridinones for the treatment of cancer diseases |
| 06/01/2006 | WO2006017214A3 Inhibitors of histone deacetylase |
| 06/01/2006 | WO2006016228A3 Cytotoxic peptide alkaloid and pharmaceutical compositions for the treatment of neoplastic diseases |
| 06/01/2006 | WO2006016067A3 Pyrido-pyrido pyrimidine derivatives, preparation thereof, therapeutic use thereof for treating cancer |
| 06/01/2006 | WO2006014918A3 Heterocyclic acetophenone potentiators of metabotropic glutamate receptors |
| 06/01/2006 | WO2006014706A3 Methotrexate derivatives useful for treating cancer and arthritis |
| 06/01/2006 | WO2006014468A3 Saif, an anti-inflammatory factor, and methods of use thereof |
| 06/01/2006 | WO2006014353A3 Glycogen or polysaccharide storage disease treatment method |
| 06/01/2006 | WO2006012603A3 Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases |
| 06/01/2006 | WO2006012078A3 Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| 06/01/2006 | WO2006005725A3 N containing condensed heterocycles with antitumor effects |
| 06/01/2006 | WO2006003068A3 Alpha-amino acid derivatives with antiinflammatory activity |
| 06/01/2006 | WO2005123051A3 Resorcinol derivatives for lowering blood pressure |
| 06/01/2006 | WO2005118537A3 Arylpiperazine derivatives as adrenergic receptor antagonists |
| 06/01/2006 | WO2005118071A3 Tetrahydropyridothiophenes |
| 06/01/2006 | WO2005117905A3 Systems and methods for treating panic attacks |
| 06/01/2006 | WO2005115365A3 Pharmaceutical or cosmetic composition comprising mequinol and at least one depigmenting agent |
| 06/01/2006 | WO2005112931A3 Methods related to the treatment of neurodegenerative and inflammatory conditions |
| 06/01/2006 | WO2005107752A3 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin |
| 06/01/2006 | WO2005102361A3 Method of producing microcrystalline cellulose containing compositions |
| 06/01/2006 | WO2005097196A3 Pharmaceutical preparation containing drospirenone for application to the skin |
| 06/01/2006 | WO2005095399A3 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors |
| 06/01/2006 | WO2005092907B1 Monosaccharide derivatives as anti-cancer and anti-inflammatory agents |
| 06/01/2006 | WO2005091987A3 Method of treating down syndrome |
| 06/01/2006 | WO2005070390A3 Mitratapide oral solution |
| 06/01/2006 | WO2005061467A3 Piperazine derivatives as bradykinin antagonists |
| 06/01/2006 | WO2005046438A3 Internal clamp for surgical procedures |
| 06/01/2006 | WO2005034940A8 Dual alanyl aminopeptidase and dipeptidyl peptidase iv inhibitors for functionally influencing different cells and for treating immunological, inflammatory, neuronal and other diseases |
| 06/01/2006 | WO2005034858A8 Compositions and methods for treatment of muscle pain and muscle wasting |
| 06/01/2006 | WO2005028481A8 Fused pentacyclic polyethers |
| 06/01/2006 | WO2005023190A3 Treatment for cd5+ b cell lymphoma |
| 06/01/2006 | WO2005014046A3 Compositions for delivery of therapeutics into the eyes and methods for making and using the same |
| 06/01/2006 | WO2004096122A3 Use of ngf antagonists and opioids for treating pain |
| 06/01/2006 | WO2004080407A3 New serotonin modulating compounds and uses therefor |
| 06/01/2006 | WO2004066932A3 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
| 06/01/2006 | WO2004004656A3 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 06/01/2006 | US20060116520 Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide |
| 06/01/2006 | US20060116518 Novel phenanthridines |
| 06/01/2006 | US20060116516 2-[[4-[[[4-(Aminosulfonyl)phenyl]methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]-4-methyl-5-thiazolecarboxylic acid, ethyl ester; 4-Methyl-2-[[4-[[[4-(methylsulfonyl)phenyl]methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]-5-thiazolecarboxylic acid, ethyl ester; Antiinflammatory agents; rheumatic diseases |
| 06/01/2006 | US20060116513 such as 11-(2-dimethylamino-ethyl)-6,11-dihydro-5-thia-11-aza-benzo[a]fluoren-8-ol and 11-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-6,11-dihydro-5-thia-11-aza-benzo [a]fluoren-8-ol; selective estrogen and androgen receptor modulators |
| 06/01/2006 | US20060116510 Isoflavone concentrates, as well as methods for their production |
| 06/01/2006 | US20060116505 Glucose and/or fructose transporter naglt1 and its gene |
| 06/01/2006 | US20060116428 Intravitreally-injectable solution for the treatment of vitreous hemorrhages |
| 06/01/2006 | US20060116427 Adapalene polymorphic forms |
| 06/01/2006 | US20060116426 Inhibitor for perioperative blood sugar elevation |
| 06/01/2006 | US20060116425 Methods and compositions for the treatment and prevention of lung disease |
| 06/01/2006 | US20060116424 Using compounds such as [4-[(N,N-diethylcarbamoyl)methoxy]-3-ethoxyphenyl]acetic acid propyl ester for inducing or maintaining anesthesia or sedation |
| 06/01/2006 | US20060116423 Methods and compositions for treatment of central nervous system injury with isothiocyanates |
| 06/01/2006 | US20060116422 Prodrugs built as multiple self-elimination-release spacers |